BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 20175870)

  • 21. Thrombotic thrombocytopenic purpura and cardiac papillary fibroelastoma: a 'unique coexistence'.
    Ramakrishnan Geethakumari P; Rubin A; Varadi G
    Blood Coagul Fibrinolysis; 2013 Dec; 24(8):881-3. PubMed ID: 24077148
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Successful treatment with rituximab in a patient with refractory thrombotic thrombocytopenic purpura refractory to plasma exchange].
    Koshino M; Kudou D; Okoshi Y; Obara N; Simizu S; Mukai HY; Suzukawa K; Hasegawa Y; Kojima H; Nagasawa T; Chiba S
    Rinsho Ketsueki; 2010 Feb; 51(2):127-31. PubMed ID: 20379104
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Clinical characteristics and outcome of 69 patients with thrombotic thrombocytopenic purpura].
    Zhang JL; Xing HZ; Wang F; Wan DM; Jiang ZX; Wang M
    Zhonghua Nei Ke Za Zhi; 2022 Jul; 61(7):797-800. PubMed ID: 35764564
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Human immunodeficiency virus associated thrombotic thrombocytopenic purpura--favourable outcome with plasma exchange and prompt initiation of highly active antiretroviral therapy.
    Hart D; Sayer R; Miller R; Edwards S; Kelly A; Baglin T; Hunt B; Benjamin S; Patel R; Machin S; Scully M
    Br J Haematol; 2011 May; 153(4):515-9. PubMed ID: 21391974
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The course of ADAMTS-13 activity and inhibitor titre in the treatment of thrombotic thrombocytopenic purpura with plasma exchange and vincristine.
    Böhm M; Betz C; Miesbach W; Krause M; von Auer C; Geiger H; Scharrer I
    Br J Haematol; 2005 Jun; 129(5):644-52. PubMed ID: 15916687
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics of plasma infusion in congenital thrombotic thrombocytopenic purpura.
    Taylor A; Vendramin C; Oosterholt S; Della Pasqua O; Scully M
    J Thromb Haemost; 2019 Jan; 17(1):88-98. PubMed ID: 30475428
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Current management and therapeutical perspectives in thrombotic thrombocytopenic purpura.
    Coppo P; Veyradier A
    Presse Med; 2012 Mar; 41(3 Pt 2):e163-76. PubMed ID: 22265954
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Severe primary refractory thrombotic thrombocytopenic purpura (TTP) in the post plasma exchange (PEX) and rituximab era.
    Goranta S; Deliwala SS; Haykal T; Bachuwa G
    BMJ Case Rep; 2020 Jun; 13(6):. PubMed ID: 32532908
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Efficacy and safety of rituximab therapy for refractory/relapsing thrombotic thrombocytopenic purpura].
    Cui J; Zhu TN; Zou N; Chen M; Zhao YQ
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2013 Feb; 35(1):116-20. PubMed ID: 23469801
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Clinical study on Rituximab in the treatment of idiopathic thrombotic thrombocytopenic purpura].
    Wang J; Wu T; Shen H; Ren C; Chen H; She Z; Wang Z
    Zhonghua Xue Ye Xue Za Zhi; 2015 Apr; 36(4):316-20. PubMed ID: 25916294
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center.
    Froissart A; Buffet M; Veyradier A; Poullin P; Provôt F; Malot S; Schwarzinger M; Galicier L; Vanhille P; Vernant JP; Bordessoule D; Guidet B; Azoulay E; Mariotte E; Rondeau E; Mira JP; Wynckel A; Clabault K; Choukroun G; Presne C; Pourrat J; Hamidou M; Coppo P;
    Crit Care Med; 2012 Jan; 40(1):104-11. PubMed ID: 21926591
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A phase-II sequential case-series study of all patients presenting to four plasma exchange centres with presumed relapsed/refractory thrombotic thrombocytopenic purpura treated with rituximab.
    Clark WF; Rock G; Barth D; Arnold DM; Webert KE; Yenson PR; Kelton JG; Li L; Foley SR;
    Br J Haematol; 2015 Jul; 170(2):208-17. PubMed ID: 25855259
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rituximab in the treatment of TTP.
    Scully M
    Hematology; 2012 Apr; 17 Suppl 1():S22-4. PubMed ID: 22507771
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Rituximab provided long-term remission in a patient with severe thrombotic thrombocytopenic purpura refractory to plasma exchange].
    Hong H; Aoyama Y; Yamamura R; Ohta T; Mugitani A; Yamane T; Hino M; Matsumoto M; Fujimura Y
    Rinsho Ketsueki; 2006 Dec; 47(12):1528-32. PubMed ID: 17233471
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Clinical characteristics of 83 patients with thrombotic thrombocytopenic purpura].
    Wang XY; Liu XF; Xue F; Liu W; Chen YF; Huang YT; Fu RF; Zhang L; Yang RC
    Zhonghua Xue Ye Xue Za Zhi; 2020 Mar; 41(3):216-221. PubMed ID: 32311891
    [No Abstract]   [Full Text] [Related]  

  • 36. Rituximab therapy for refractory thrombotic thrombocytopenic purpura.
    Gutterman LA; Kloster B; Tsai HM
    Blood Cells Mol Dis; 2002; 28(3):385-91. PubMed ID: 12367582
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of ADAMTS13 in the management of thrombotic microangiopathies including thrombotic thrombocytopenic purpura (TTP).
    Shah N; Rutherford C; Matevosyan K; Shen YM; Sarode R
    Br J Haematol; 2013 Nov; 163(4):514-9. PubMed ID: 24111495
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treating thrombotic thrombocytopenic purpura without plasma exchange during the COVID-19 pandemic. A case report and a brief literature review.
    Galindo-Calvillo CD; Rodríguez-Roque CS; Gómez-De León A; Tarín-Arzaga L; Gómez-Almaguer D
    Transfus Apher Sci; 2021 Jun; 60(3):103107. PubMed ID: 33714651
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rituximab for the treatment of refractory idiopathic thrombocytopenic purpura (ITP) and thrombotic thrombocytopenic purpura (TTP): report of three cases.
    Koulova L; Alexandrescu D; Dutcher JP; O'Boyle KP; Eapen S; Wiernik PH
    Am J Hematol; 2005 Jan; 78(1):49-54. PubMed ID: 15609292
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases.
    Fakhouri F; Vernant JP; Veyradier A; Wolf M; Kaplanski G; Binaut R; Rieger M; Scheiflinger F; Poullin P; Deroure B; Delarue R; Lesavre P; Vanhille P; Hermine O; Remuzzi G; Grünfeld JP
    Blood; 2005 Sep; 106(6):1932-7. PubMed ID: 15933059
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.